As Ozempic and other GLP-1 drugs explode in popularity, driven by their off-label use for rapid weight loss and viral social media trends, the pharmaceutical industry faces unprecedented challenges.

Eisai has been steadily building up expertise in the use of digital health systems to support people with dementia but has now gone one step further – launching a dedicated subsidiary company to ...